Previous 10 | Next 10 |
Prognostic gene expression profile test for metastatic risk in cutaneous squamous cell carcinoma now available to clinicians in the U.S. Conference Call and webcast today at 4:30 p.m. ET Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personali...
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced leadership promotions and a new medical director. Toby Juvenal has been promoted to Chief Commercial Officer. Juvena...
Webcast to be held September 2, 2020 at 4:30 pm ET Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that it will be holding a conference call on September 2, 2020...
Castle Biosciences, Inc. (CSTL) Q2 2020 Earnings Conference Call August 10, 2020 04:30 pm ET Company Participants Frank Stokes - Chief Financial Officer Derek Maetzold - Founder, President and Chief Executive Officer Conference Call Participants Puneet Souda - SVB Leerink S...
The following slide deck was published by Castle Biosciences, Inc. in conjunction with their 2020 Q2 earnings Read more ...
Castle Biosciences (NASDAQ: CSTL ) : Q2 GAAP EPS of -$0.08 beats by $0.32 . More news on: Castle Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that Derek Maetzold, president and chief executive officer, is scheduled to present a company overview at the Canaccord ...
Study Published Recently in O cular Oncology and Pathology Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the publication of a multicenter, prospective study dem...
Published Recently in SKIN: The Journal of Cutaneous Medicine Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the publication of an independent, systematic revie...
Castle Biosciences, Inc. (Nasdaq: CSTL), announced today that the underwriters of its recently closed underwritten public offering of 2,000,000 shares of its common stock have exercised in full their option to purchase an additional 300,000 shares of common stock at the public offering price ...
News, Short Squeeze, Breakout and More Instantly...
Castle Biosciences Inc. Company Name:
CSTL Stock Symbol:
NASDAQ Market:
Castle Biosciences Inc. Website:
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Canaccord Genuity 44 th Annual Growth Conference on Tuesday, Aug. 13, 2024, at ...
Campaign will focus on empowering patients impacted by melanoma Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has joined forces with television personality, wellness coach and founder of ALL IN by Teddi, host of the...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter and six months ended June 30, 2024, after the close of market on Monday, Aug. 5, 2024. Compan...